therapeutically effective amount of or (a) A2D ligand or (b) SSRI A pharmaceutical composition comprising an active agent selected acceptable salts, from a mixture of (c) and a pharmaceutically acceptable salt of the prodrug or the SNRI or prodrug thereof, or (c) SNRI (b) and is also ...
Patients were aged over 17 years, were being treated for depression in primary care, and had been taking an SSRI or SNRI antidepressant for at least six weeks. They were still depressed using International Classification of Diseases (ICD-10) criteria. All 480 patients who took part continued to...
For example, while it is well-known that certain SSRI's (e.g. paroxetine) or SNRI's (e.g. venlafaxine) are capable of alleviating hot flashes, it is generally accepted that they do not have the efficacy of estrogen-containing treatments and may have side effects as well (e.g. sexual...
抗抑郁药(如5-羟色胺和去甲肾上腺素再摄取抑制剂,SNRI) 的疗效是否优于选择性强的药物(如选择性5-羟色胺再摄取 抑制剂,SSRI)。对此,已有的研究给出了不同的结论 [5-6] 。同 样,迄今仍没有令人信服的证据表明,多种作用机制相同或相 近的抗抑郁药联用疗效优于单一用药 [7-8] ;而作用机制不同或 者...
Certain embodiments provide a first neurogenic agent and a second neurogenic agent in combination in a single formulation, wherein the first agent is an inhibitor of 3 hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR); and the second agent is a selective 10 serotonin reuptake inhibitor (SSRI). In...
The present invention, a dual serotonin and alpha-2-delta ligand - one or both noradrenaline re-uptake inhibitor, or (DSNRI) selective serotonin reuptake inhibitors (SSRI) and selective noradrenaline reuptake inhibitor (SNRI), and combinations of salts pharmaceutically acceptable thereof, especially a...
Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disordersnot available for EP1675582of corresponding document: WO2005025563 A method is provided of treating depression in mammals, including a human, as well as depression and a ...
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI, a NARI, a dual SSRI/NARI (a SNRI), or a tricyclic antidepressant (TCA). It has unexpectedly...
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI, a NARI, a dual SSRI/NARI (a SNRI), or a tricyclic antidepressant (TCA). It has unexpectedly...
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI, a NARI, a dual SSRI/NARI (a SNRI), or a tricyclic antidepressant (TCA). It has unexpectedly...